The original success of Sildenafil undeniably transformed the pharmaceutical landscape, but betting in companies strongly reliant on unbranded versions presents a complex picture. Although early earnings were substantial, the end of patents and the rise of cheaper alternatives have eroded sales. Consequently, a thorough assessment of present revenu